D. D. Wang

Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients.

Y. Yu, C. Durairaj, H. Shi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials.

I. C. Tudor, N. Turner, A. Czibere, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial.

I. C. Tudor, A. Czibere, J. Litton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

462PA POPULATION PHARMACOKINETIC (PK) ANALYSIS OF PALBOCICLIB (PD-0332991) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS.

D. D. Wang, W. Sun, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Absolute bioavailability of PF-01367338 tablets following oral administration in cancer patients.

R. Plummer, K. Kern, J. Spicer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative PARP enzyme inhibition of PF-01367338, olaparib, and MK-4827.

K. Kern, D. Shalinsky, S. Zhang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.